359 related articles for article (PubMed ID: 23241899)
21. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
Front Immunol; 2018; 9():1990. PubMed ID: 30298063
[TBL] [Abstract][Full Text] [Related]
22. [Research progress of gammadelta T cell-based immunotherapy].
Qiu FM; Li ZP; Huang J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 39(4):424-9. PubMed ID: 20731045
[TBL] [Abstract][Full Text] [Related]
23. γδ T cells in immunotherapies for B-cell malignancies.
Rimailho L; Faria C; Domagala M; Laurent C; Bezombes C; Poupot M
Front Immunol; 2023; 14():1200003. PubMed ID: 37426670
[TBL] [Abstract][Full Text] [Related]
24. Anti-lymphoma effect of gammadelta T cells.
Kunzmann V; Wilhelm M
Leuk Lymphoma; 2005 May; 46(5):671-80. PubMed ID: 16019504
[TBL] [Abstract][Full Text] [Related]
25. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.
Martinet L; Poupot R; Fournié JJ
Immunol Lett; 2009 May; 124(1):1-8. PubMed ID: 19465238
[TBL] [Abstract][Full Text] [Related]
26. γδ cells and tumor microenvironment: A helpful or a dangerous liason?
Lo Presti E; Di Mitri R; Pizzolato G; Mocciaro F; Dieli F; Meraviglia S
J Leukoc Biol; 2018 Mar; 103(3):485-492. PubMed ID: 29345336
[TBL] [Abstract][Full Text] [Related]
27. Gamma-delta (γδ) T cells: friend or foe in cancer development?
Zhao Y; Niu C; Cui J
J Transl Med; 2018 Jan; 16(1):3. PubMed ID: 29316940
[TBL] [Abstract][Full Text] [Related]
28. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
Gomes AQ; Martins DS; Silva-Santos B
Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
[TBL] [Abstract][Full Text] [Related]
29. Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators?
Riganti C; Massaia M; Davey MS; Eberl M
Eur J Immunol; 2012 Jul; 42(7):1668-76. PubMed ID: 22806069
[TBL] [Abstract][Full Text] [Related]
30. The emerging roles of γδ T cells in cancer immunotherapy.
Mensurado S; Blanco-Domínguez R; Silva-Santos B
Nat Rev Clin Oncol; 2023 Mar; 20(3):178-191. PubMed ID: 36624304
[TBL] [Abstract][Full Text] [Related]
31. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
[TBL] [Abstract][Full Text] [Related]
32. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
Norell H; Moretta A; Silva-Santos B; Moretta L
J Leukoc Biol; 2013 Dec; 94(6):1123-39. PubMed ID: 24108703
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.
Saitoh A; Narita M; Watanabe N; Tochiki N; Satoh N; Takizawa J; Furukawa T; Toba K; Aizawa Y; Shinada S; Takahashi M
Med Oncol; 2008; 25(2):137-47. PubMed ID: 18488155
[TBL] [Abstract][Full Text] [Related]
34. Pro-tumor γδ T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy.
Chabab G; Barjon C; Bonnefoy N; Lafont V
Front Immunol; 2020; 11():2186. PubMed ID: 33042132
[TBL] [Abstract][Full Text] [Related]
35. Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.
Alexander AA; Maniar A; Cummings JS; Hebbeler AM; Schulze DH; Gastman BR; Pauza CD; Strome SE; Chapoval AI
Clin Cancer Res; 2008 Jul; 14(13):4232-40. PubMed ID: 18594005
[TBL] [Abstract][Full Text] [Related]
36. The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy.
Van Acker HH; Campillo-Davo D; Roex G; Versteven M; Smits EL; Van Tendeloo VF
Cytokine Growth Factor Rev; 2018 Jun; 41():54-64. PubMed ID: 29773448
[TBL] [Abstract][Full Text] [Related]
37. Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial.
Kunzmann V; Smetak M; Kimmel B; Weigang-Koehler K; Goebeler M; Birkmann J; Becker J; Schmidt-Wolf IG; Einsele H; Wilhelm M
J Immunother; 2012; 35(2):205-13. PubMed ID: 22306909
[TBL] [Abstract][Full Text] [Related]
38. γδ T cells: Major advances in basic and clinical research in tumor immunotherapy.
Zhao Y; Dong P; He W; Zhang J; Chen H
Chin Med J (Engl); 2024 Jan; 137(1):21-33. PubMed ID: 37592858
[TBL] [Abstract][Full Text] [Related]
39. [Cancer immunotherapy using gammadelta T cells ex vivo expanded by bisphosphonate].
Kimura S
Clin Calcium; 2008 Apr; 18(4):499-505. PubMed ID: 18379032
[TBL] [Abstract][Full Text] [Related]
40. Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.
Meraviglia S; Caccamo N; Guggino G; Tolomeo M; Siragusa S; Stassi G; Dieli F
Curr Mol Med; 2010 Nov; 10(8):719-26. PubMed ID: 20937023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
